Dear Reader,
Everyone knows Elon Musk for Tesla.
Some know him as an early investor in PayPal.
But very few investors realize Musk has quietly built something else entirely…
A massive global network that could power the next phase of artificial intelligence.
Right now, thousands of these systems are already operating around the world.
They run day and night…
With minimal human input.
And Elon Musk believes this technology could ultimately help Tesla become:
“The most valuable company in the world.”
But here’s the surprising part.
The core infrastructure behind this project isn’t owned by Tesla.
It’s owned by one of Elon Musk’s private ventures.
And while most investors assume private companies are impossible to access…
Veteran tech investor Matt McCall recently revealed a little-known way everyday investors can gain exposure.
Right now the stock involved trades for less than $30.
Here’s to the future,
Matt McCall
Amprius Stock Is Flashing One Signal That Traders Rarely Ignore
Author: Thomas Hughes. Posted: 3/9/2026.
Key Points
- Amprius Technologies' trading volume is a signal investors and traders should heed, as it reflects growing conviction in the stock's future price.
- The fiscal Q4 2025 earnings report affirmed a robust, hypergrowth pace that analysts have underestimated.
- Analysts and institutional trends align with technical signals, revealing that this market is accumulating stock.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Amprius (NYSE: AMPX) stock is poised to move higher because its technical signals, supported by a strong fundamental outlook, converge with the single signal that matters most: trading volume.
An increase or decrease in trading volume reveals whether the market is actually buying the stock.
Elon Musk: This Could Turn $100 into $100,000 (Ad)
What if you could shrink your entire wealth journey from decades down to just 24 hours?
Sounds impossible…
But I'll show you how Elon Musk is about to make it a reality.
This could be the best investment opportunity of the decade.Without rising volume, otherwise strong signals are far more likely to fizzle out as false breakouts than to sustain gains for investors.
Trading volume is critical for price action because it reveals market conviction — a firmly held belief about value. Volume validates trends, acts as a leading indicator of continuation or reversal, indicates liquidity, and signals institutional activity.
Amprius' trading volume is notable for several reasons. Volume ramped alongside price action in 2025 and 2026 as price broke out to fresh highs. That pattern appears on the daily and weekly charts and was already approaching record monthly volume in early March.
Record-setting days and weeks have been logged. Trading volume on the day of AMPX's fiscal Q4 2025 earnings release was more than four times the 30-day average and remained at elevated levels the following day, creating a weekly spike with similar metrics.
Amprius Technologies Volume Spiked for a Reason
Amprius Technologies' volume spike was backed by fundamentals: its Q4 earnings release affirmed a robust outlook. The company's silicon‑anode lithium‑ion batteries deliver greater energy density and discharge capacity, enabling larger payloads and longer ranges across vehicle and system platforms. Demand for those capabilities is increasing.
For 2026, key developments are clear: contract-manufacturing is scaling, production is ramping, demand remains solid, and compliance with the National Defense Authorization Act has improved, opening broader access to government and defense opportunities. That combination lifted the revenue outlook and produced stronger guidance; analysts' hyper-growth forecasts may still be conservative.
Analyst and Institutional Trends Reveal Amprius Stock Is Being Accumulated
The analyst and institutional footprints are still modest — coverage is light and institutional holdings are small — but three tailwinds are in place. First, analyst coverage has been increasing, which supports greater exposure and investor interest.
Second, sentiment has improved: four of the nine analysts tracked by MarketBeat issued updates after the Q4 release. Third, institutional investors are accumulating. While holdings are around 5% as of early March, the trailing‑12‑month balance is strongly bullish, with institutions buying nearly $6 of shares for each $1 sold.
Analyst sentiment has also trended bullish. Coverage has increased by nearly 30% in recent months, consensus sentiment sits at Moderate Buy, nearly 90% of updates favor Buy, and price targets are rising.
The consensus implies roughly 12% upside from a key resistance point, but high‑end targets are in the low‑$20s, suggesting roughly 30% upside is possible, potentially by midyear.
Technical Signals Converge: Amprius Price Action to Head Higher
Amprius' price action reached a critical juncture shortly after the Q4 release, trading near resistance at the top of a channel. While that channel top could cap near‑term gains, indicators on daily, weekly, and monthly charts point higher: price action, trading volume, stochastic, and moving average convergence divergence (MACD) are aligning.
AMPX looks likely to break out of the channel, retest the breakout (confirming the top as support), and accelerate. It could quickly reach the high end of analyst expectations and continue upward, potentially testing all‑time highs well before year‑end. Catalysts for that move are already in place — upcoming news and earnings could add momentum. Given its potential to disrupt global battery markets, AMPX stock could rise 200% to 300% over the next year or two.
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
Authored by Jordan Chussler. Article Published: 3/10/2026.
Key Points
- Hims & Hers has shifted from offering controversial compounded GLP-1s to a formal agreement with Novo Nordisk, allowing the platform to distribute FDA-approved Ozempic and Wegovy.
- Following the announcement, HIMS shares surged nearly 46%, helping the stock recover from a 59% drop earlier in the year caused by previous legal friction with Novo Nordisk.
- Analysts have upgraded the stock, citing the partnership as a major growth catalyst; despite a year-to-date loss, earnings are projected to grow by over 79% next year.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares surge following an agreement with GLP-1 maker Novo Nordisk (NYSE: NVO)—the same company that filed a patent infringement lawsuit against Hims & Hers on Feb. 9.
After pulling its compounded semaglutide product modeled on Novo Nordisk's weight-loss drugs Wegovy and Ozempic, Hims & Hers announced in a press release that the two firms have entered into a strategic partnership to make Novo Nordisk's obesity drugs available through Hims & Hers' telehealth platform.
Elon Musk: This Could Turn $100 into $100,000 (Ad)
What if you could shrink your entire wealth journey from decades down to just 24 hours?
Sounds impossible…
But I'll show you how Elon Musk is about to make it a reality.
This could be the best investment opportunity of the decade.Since the announcement, HIMS has gained nearly 46% and seen analyst upgrades as Wall Street grows more bullish on the direct-to-consumer prescription drug provider.
A Strategic Shift From Compounded GLP-1 to FDA-Approved Drugs
Amid surging demand and subsequent shortages for weight-loss drugs, compounded GLP-1 alternatives emerged to fill the void. However, compounded GLP-1 products do not have U.S. Food and Drug Administration (FDA) approval.
They did help increase affordable access to substitutes for brand-name drugs like Ozempic and Wegovy and often contained similar active ingredients (for example, semaglutide and tirzepatide, the latter marketed as Mounjaro and Zepbound). But without FDA review, these alternatives lacked standardized quality and efficacy assessments, creating risks related to incorrect dosages, improper storage and other safety issues.
According to Hims & Hers's press release, as part of the company's shift away from compounded GLP-1 offerings, "existing patients will have the opportunity to transition to FDA-approved medicines."
Specifically, "Hims & Hers has entered into an agreement with Novo Nordisk that will bring Ozempic (semaglutide) 0.5 mg, 1 mg, and 2 mg injections and Wegovy (semaglutide) pills and injections to the platform later this month, including 1.7 mg or 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, and 25 mg tablets."
Co-founder and CEO Andrew Dudum said the deal should create "tremendous growth opportunities in the U.S. with the expanding assortment of branded GLP-1 medications." He added that the "collaboration reflects what's possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations."
Shares of HIMS Are Still Struggling, But the Future Looks Promising
The news and the sizable bump in the stock price were welcomed by shareholders who have endured Hims & Hers' volatility over the past year. Even after the Novo Nordisk–related sell-off in February, some analysts remained bullish, with certain 12-month price targets implying as much as 150% potential upside.
Despite the March 9 surge, HIMS shares are still down nearly 33% over the last 12 months. Still, the company appears fundamentally well-positioned to sustain growth.
When Hims & Hers reported full-year and Q4 2025 earnings on Feb. 23, it posted an earnings-per-share (EPS) beat and a slight revenue miss. EPS of $0.08 topped analyst expectations of $0.02, while revenue of $617.82 million fell short of consensus $619.48 million.
It was the company's first EPS beat since the first quarter of last year. More importantly, the financials showed steady, sustainable revenue growth, with a three-year average of 64.60%. While earnings contracted in 2025, that followed EPS growth of nearly 582% in 2024 and about 66% in 2023.
Hims & Hers Health's earnings are expected to rise roughly 79.31% next year, from $0.29 per share to about $0.52 per share.
HIMS Receives Analyst Upgrades as Wall Street Turns Bullish on Telehealth
After the Novo Nordisk deal was announced, Bank of America Securities upgraded HIMS to Neutral from Underperform and raised its price target to $23 from $12.50.
Notably, the firm's previous price target excluded contributions from GLP-1 revenue, suggesting the Novo Nordisk agreement is being viewed as a highly bullish catalyst by Wall Street.
Overall, the stock carries a consensus Hold rating from 17 analysts covering the name. The average one-year price target implies more than 32% potential upside.
Current short interest sits at 43.24% of shares outstanding and should be watched. That level, which represents roughly $1.32 billion worth of shares, is substantially lower than the $4.27 billion that were shorted last July. The downward trend in short interest has continued, and it would not be surprising if institutional buyers increase their holdings in coming quarters as the Novo Nordisk deal helps bolster Hims & Hers' top-line growth.
to bring you the latest market-moving news.
This email message is a paid sponsorship from NXT Wave Research, a third-party advertiser of TickerReport and MarketBeat.
Contact Us | Unsubscribe
© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights reserved.
345 North Reid Place #620, Sioux Falls, SD 57103. United States of America..
0 Response to "Elon’s “Hidden” Company"
Post a Comment